These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 34146854)
61. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Li BH; He FP; Yang X; Chen YW; Fan JG Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593 [TBL] [Abstract][Full Text] [Related]
62. GCN2 deficiency protects against high fat diet induced hepatic steatosis and insulin resistance in mice. Liu S; Yuan J; Yue W; Bi Y; Shen X; Gao J; Xu X; Lu Z Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3257-3267. PubMed ID: 30006154 [TBL] [Abstract][Full Text] [Related]
63. Combination of luteolin and lycopene effectively protect against the "two-hit" in NAFLD through Sirt1/AMPK signal pathway. Zhu Y; Liu R; Shen Z; Cai G Life Sci; 2020 Sep; 256():117990. PubMed ID: 32574665 [TBL] [Abstract][Full Text] [Related]
64. Hepatoprotective effect of trypsin/chymotrypsin against olanzapine-induced non-alcoholic steatohepatitis in rats. Mahmoud GS; Hosny G; Sayed SA Can J Physiol Pharmacol; 2021 Oct; 99(10):1088-1096. PubMed ID: 34473596 [TBL] [Abstract][Full Text] [Related]
65. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease. Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769 [TBL] [Abstract][Full Text] [Related]
66. Prolactin improves hepatic steatosis via CD36 pathway. Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209 [TBL] [Abstract][Full Text] [Related]
67. Circulating ectodysplasin A is a potential biomarker for nonalcoholic fatty liver disease. Yang J; Zhou W; Zhu J; Wu Y; Xu L; Wang Y; Zhang Q; Yang Y Clin Chim Acta; 2019 Dec; 499():134-141. PubMed ID: 31526774 [TBL] [Abstract][Full Text] [Related]
68. CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice. Chen G; Xu R; Zhang S; Wang Y; Wang P; Edin ML; Zeldin DC; Wang DW Am J Physiol Endocrinol Metab; 2015 Jan; 308(2):E97-E110. PubMed ID: 25389366 [TBL] [Abstract][Full Text] [Related]
69. Angiotensinogen in hepatocytes contributes to Western diet-induced liver steatosis. Tao XR; Rong JB; Lu HS; Daugherty A; Shi P; Ke CL; Zhang ZC; Xu YC; Wang JA J Lipid Res; 2019 Dec; 60(12):1983-1995. PubMed ID: 31604805 [TBL] [Abstract][Full Text] [Related]
73. Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells. Hao L; Ito K; Huang KH; Sae-tan S; Lambert JD; Ross AC Metabolism; 2014 Oct; 63(10):1352-62. PubMed ID: 25060692 [TBL] [Abstract][Full Text] [Related]
74. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6. Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567 [TBL] [Abstract][Full Text] [Related]
75. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease. Fu D; Cui H; Zhang Y Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812 [TBL] [Abstract][Full Text] [Related]
76. Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. Caputo M; Kurhe Y; Kumari S; Cansby E; Amrutkar M; Scandalis E; Booten SL; Ståhlman M; Borén J; Marschall HU; Aghajan M; Mahlapuu M FASEB J; 2021 May; 35(5):e21567. PubMed ID: 33891332 [TBL] [Abstract][Full Text] [Related]
77. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease. Teng W; Zhao L; Yang S; Zhang C; Liu M; Luo J; Jin J; Zhang M; Bao C; Li D; Xiong W; Li Y; Ren F J Control Release; 2019 Aug; 307():139-149. PubMed ID: 31233775 [TBL] [Abstract][Full Text] [Related]
78. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease. Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394 [TBL] [Abstract][Full Text] [Related]
79. ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content. Camporez JPG; Kanda S; Petersen MC; Jornayvaz FR; Samuel VT; Bhanot S; Petersen KF; Jurczak MJ; Shulman GI J Lipid Res; 2015 Mar; 56(3):526-536. PubMed ID: 25548259 [TBL] [Abstract][Full Text] [Related]
80. Triterpenic acids-enriched fraction from Cyclocarya paliurus attenuates insulin resistance and hepatic steatosis via PI3K/Akt/GSK3β pathway. Zheng X; Zhao MG; Jiang CH; Sheng XP; Yang HM; Liu Y; Yao XM; Zhang J; Yin ZQ Phytomedicine; 2020 Jan; 66():153130. PubMed ID: 31790897 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]